1
|
Sánchez-Albisua I, Schöning M, Jurkat-Rott K, Lerche H. Possible effect of corticoids on hemiplegic attacks in severe hemiplegic migraine. Pediatr Neurol 2013; 49:286-8. [PMID: 23831250 DOI: 10.1016/j.pediatrneurol.2013.04.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Revised: 03/25/2013] [Accepted: 04/11/2013] [Indexed: 11/15/2022]
Abstract
BACKGROUND Sporadic and familial hemiplegic migraines are rare paroxysmal disorders characterized by transient hemiparesis and headache. The distinction is based on whether other family members are affected. In 50% of cases, these migraines are caused by CACNA1 A missense mutations. PATIENTS We describe a boy with a particularly severe phenotype and a de novo R1349Q mutation of the CACNA1 A gene. RESULTS The patient suffered from early-onset profound mental retardation, epileptic seizures, cerebellar ataxia, and progressive cerebellar atrophy. He experienced prolonged attacks of migraine with hemiparesis, seizures, altered consciousness, and fever resulting from minor head traumas. A prolonged hemiplegic attack improved following a 5-day treatment of 100 mg/d methylprednisolone. CONCLUSION R1349Q mutation of the CACN1 A gene may be associated with a severe phenotype. Corticoids might be beneficial in prolonged hemiplegic attacks.
Collapse
Affiliation(s)
- Iciar Sánchez-Albisua
- Department of Child Neurology, Children's Hospital, University of Tübingen, Germany.
| | | | | | | |
Collapse
|
2
|
Knierim E, Leisle L, Wagner C, Weschke B, Lucke B, Bohner G, Dreier JP, Schuelke M. Recurrent Stroke Due to a Novel Voltage Sensor Mutation in Ca
v
2.1 Responds to Verapamil. Stroke 2011; 42:e14-7. [DOI: 10.1161/strokeaha.110.600023] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Ellen Knierim
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| | - Lilia Leisle
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| | - Christiane Wagner
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| | - Bernhard Weschke
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| | - Barbara Lucke
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| | - Georg Bohner
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| | - Jens P. Dreier
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| | - Markus Schuelke
- From the Department of Neuropediatrics (E.K., C.W., B.W., B.L., M.S.), the NeuroCure Clinical Research Center (E.K., B.L., M.S.), the Department of Neuroradiology (G.B.), and the Center for Stroke Research (J.P.D.), Charité Universitätsmedizin Berlin, Berlin, Germany; and the Leibniz-Institute for Molecular Pharmacology and Max-Delbrueck-Center for Molecular Medicine (L.L.), Berlin, Germany
| |
Collapse
|